Maria got the diagnosis at her 20-week ultrasound: Her baby, Calista, had hypoplastic left heart syndrome, or HLHS. As an emergency department nurse in Greeley, Colorado, Maria had an idea of what that meant. What she didn’t know, she got right to work finding out. It didn’t take her long to hone in on stem cells.
Kids with HLHS face a grim prognosis. The right ventricle, normally responsible only for pulmonary circulation, has to pump blood through the entire body on its own. And the trifecta of HLHS surgeries that reconfigure the circulation to make that possible, while lifesaving, don’t happen without scarring. Scarring, in turn, further weakens the myocardium.
Stem cells don't survive in myocardial tissue, but they do secrete substances that can attract other cells to strengthen and possibly replace damaged heart muscle cells.
That research, and research like it, drives the mission of the Mayo Clinic's HLHS consortium, a multi-institutional group now harvesting patients' own umbilical cells at birth to inject back into their hearts during staged reconstruction. Through such injections, cardiothoracic surgeons like Dr. Jaggers hope to minimize scarring and promote regeneration in areas affected by surgery — maybe even strengthen the right ventricle and help it function like the left.
"The important thing is the power of multiple heart programs all working toward the same goal."